These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32223599)

  • 1. Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support.
    Garrison LP; Zamora B; Li M; Towse A
    J Manag Care Spec Pharm; 2020 Apr; 26(4):400-406. PubMed ID: 32223599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts.
    Kannarkat JT; Good CB; Kelly E; Parekh N
    J Manag Care Spec Pharm; 2020 Jan; 26(1):63-66. PubMed ID: 31880231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.
    Garrison LP; Neumann PJ; Willke RJ
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1185-1192. PubMed ID: 31663458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Employer and Plan Sponsor Views on Pharmacy Reimbursement.
    Stull M; Gupton C
    J Manag Care Spec Pharm; 2020 Jun; 26(6):710-712. PubMed ID: 32463776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailoring access to high cost, genetically targeted drugs.
    Hall WD; Ward R; Liauw WS; Lu CY; Brien JA
    Med J Aust; 2005 Jun; 182(12):607-8. PubMed ID: 15963014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of randomized controlled trials in organizational decision making: a cost-minimization approach.
    Cher DJ; Maclure M
    Am J Manag Care; 2000 Aug; 6(8):894-904. PubMed ID: 11186501
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?
    Wonder M; Dunlop S
    Value Health; 2015 Jun; 18(4):467-76. PubMed ID: 26091601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should national pharmacare apply a value-based insurance design?
    Yeung K; Morgan SG
    CMAJ; 2019 Jul; 191(29):E811-E815. PubMed ID: 31332049
    [No Abstract]   [Full Text] [Related]  

  • 9. Using the Delphi method to identify meaningful and feasible outcomes for pharmaceutical value-based contracting.
    Swart ECS; Parekh N; Daw J; Manolis C; Good CB; Neilson LM
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1385-1389. PubMed ID: 33119437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold.
    Garrison LP; Jackson T; Paul D; Kenston M
    J Manag Care Spec Pharm; 2019 Jul; 25(7):793-799. PubMed ID: 30784347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using pharmaceutical cost analyses for decision making.
    U'Ren NA
    Hosp Cost Manag Account; 1997 Nov; 9(8):1-7. PubMed ID: 10178832
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program.
    Etemad LR; Hay JW
    Value Health; 2003; 6(4):425-35. PubMed ID: 12859583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saying no isn't NICE - the travails of Britain's National Institute for Health and Clinical Excellence.
    Steinbrook R
    N Engl J Med; 2008 Nov; 359(19):1977-81. PubMed ID: 18987366
    [No Abstract]   [Full Text] [Related]  

  • 15. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value-Based Pharmaceutical Contracts: Value for Whom?
    Kannarkat JT; Good CB; Parekh N
    Value Health; 2020 Feb; 23(2):154-156. PubMed ID: 32113619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory, Policy, and Operational Considerations for Outcomes-Based Risk-Sharing Agreements in the U.S. Market: Opportunities for Reform.
    Goodman C; Villarivera C; Gregor K; van Bavel J
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1174-1181. PubMed ID: 31535596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?
    Chambers JD
    Pharmacoeconomics; 2014 Aug; 32(8):729-33. PubMed ID: 24859242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward Relevant and Credible Cost-Effectiveness Analyses for Value Assessment in the Decentralized U.S. Health Care System.
    Jansen JP; Incerti D; Curtis JR
    J Manag Care Spec Pharm; 2019 May; 25(5):518-521. PubMed ID: 31039069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Approaches to Value Assessment Beyond the Cost-Effectiveness Framework.
    Reed SD; Dubois RW; Johnson FR; Caro JJ; Phelps CE
    Value Health; 2019 Jun; 22(6S):S18-S23. PubMed ID: 31200802
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.